Skip to content

Clinical Application and Mechanism Research of Activating Spleen to Eliminate Turbid Therapy Based on the Vascular Microenvironment in the Intervention of Atherosclerosis

Clinical Application and Mechanism Research of Activating Spleen to Eliminate Turbid Therapy Based on the Vascular Microenvironment in the Intervention of Atherosclerosis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005770
Enrollment
Unknown
Registered
2021-07-11
Start date
2021-07-10
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia with carotid artery plaque

Interventions

Sponsors

Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with 50% carotid stenosis and 50%-69% carotid stenosis were selected, The diagnostic criteria for carotid artery stenosis refer to Carotid Artery Stenosis: Gray-Scale and Doppler US Diagnosis--Society of Radiologists in Ultrasound Consensus Conference; 2. Patients with dyslipidemia were selected, The diagnostic criteria for dyslipidemia refer to Guidelines for the prevention and treatment of dyslipidemia in adults in China (2016 revision),or biochemical assay of patients: TG >= 2.30mmol/L; 6.11mmol/L <= TC; 3.37mmol/L <= LDL-C; Any one of the above indicators is abnormal and TC < 7.2mmol/L, LDL-C<4.9mmol/L can be included in the group; 3. The TCM syndrome type is phlegm and blood stasis block syndrome; 4. Aged 25-80 years; 5. Voluntarily participate in this clinical study and sign the informed consent form, insist on taking the medicine for 8 weeks, and complete the pre-treatment and post-treatment scale filling, blood test examination, and a fixed contact information to complete the follow-up work.

Exclusion criteria

Exclusion criteria: 1. Dyslipidemia caused by hypothyroidism, gout and nephrotic syndrome; patients with homozygous familial hypercholesterolemia; dyslipidemia caused by acute and chronic hepatobiliary diseases; Dyslipidemia caused by blockers, adrenal corticosteroids and some contraceptives, etc.); 2. Patients with serious primary diseases such as liver, kidney and hematopoietic system and mental illness; 3. Patients with hypertension grade III, acute coronary syndrome and cardiac function grade III-IV; patients with acute myocardial infarction, cerebrovascular accident, severe trauma or major surgery within 0.5 years; pregnant or lactating women; allergic constitution and allergic to the test drug; 4. Ultrasound showed that the plaque caused the carotid artery lumen stenosis >=70%, which seriously affected the carotid artery blood flow.

Design outcomes

Primary

MeasureTime frame
Biochemical assay (TC, TG, LDL-C, HDL-C);Between-group differences in the annualized change in mean IMT of 12 sites of bilateral carotid arteries;Major cardiovascular events;

Secondary

MeasureTime frame
adverse events;life quality evaluation;Vascular remodeling index;inflammatory cytokine (IL-6, TNF-10, hs-CRP);Maximal plaque area;

Countries

China

Contacts

Public ContactHe Qingyong

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

heqingyongg@163.com+86 88001817

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026